Literature DB >> 33143429

VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons.

Brittany D Spitznagel1, Nigam M Mishra2, Alshaima'a M Qunies2,3, Francis J Prael1,4, Yu Du1,4, Krystian A Kozek1,4,5, Roman M Lazarenko6, Jerod S Denton1,6, Kyle A Emmitte2, C David Weaver1,4.   

Abstract

Malignant migrating partial seizures of infancy is a rare, devastating form of epilepsy most commonly associated with gain-of-function mutations in the potassium channel, Slack. Not only is this condition almost completely pharmacoresistant, there are not even selective drug-like tools available to evaluate whether inhibition of these overactivated, mutant Slack channels may represent a viable path forward toward new antiepileptic therapies. Therefore, we used a high-throughput thallium flux assay to screen a drug-like, 100 000-compound library in search of inhibitors of both wild-type and a disease-associated mutant Slack channel. Using this approach, we discovered VU0606170, a selective Slack channel inhibitor with low micromolar potency. Critically, VU0606170 also proved effective at significantly decreasing the firing rate in overexcited, spontaneously firing cortical neuron cultures. Taken together, our data provide compelling evidence that selective inhibition of Slack channel activity can be achieved with small molecules and that inhibition of Slack channel activity in neurons produces efficacy consistent with an antiepileptic effect. Thus, the identification of VU0606170 provides a much-needed tool for advancing our understanding of the role of the Slack channel in normal physiology and disease as well as its potential as a target for therapeutic intervention.

Entities:  

Keywords:  KCNT1; MMPSI; Slack channel; epilepsy; inhibitor; small molecule

Mesh:

Substances:

Year:  2020        PMID: 33143429     DOI: 10.1021/acschemneuro.0c00583

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

Review 1.  Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.

Authors:  Alshaima'a M Qunies; Kyle A Emmitte
Journal:  Pharm Pat Anal       Date:  2022-04-04

2.  Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series.

Authors:  Andrew M Griffin; Kristopher M Kahlig; Robert John Hatch; Zoë A Hughes; Mark L Chapman; Brett Antonio; Brian E Marron; Marion Wittmann; Gabriel Martinez-Botella
Journal:  ACS Med Chem Lett       Date:  2021-03-09       Impact factor: 4.345

3.  KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons.

Authors:  Tracy S Gertler; Suraj Cherian; Jean-Marc DeKeyser; Jennifer A Kearney; Alfred L George
Journal:  Neurobiol Dis       Date:  2022-03-26       Impact factor: 7.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.